Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
Trial design: 751 adults with obesity (BMI 30, or 27 with at least one comorbidity) No type 2 diabetes 72-week follow-up Tirzepatide 10mg or 15mg vs Semaglutide 2.4mg Results at 72 weeks: When looking at tirzepatide weight loss results from SURMOUNT-5 alongside semaglutide weight loss results from the STEP trials, the gap is consistent and statistically significant across every subgroup sex, age, baseline BMI, and presence of metabolic comorbidities
If the results of these trials are positive, it will open a new horizon in the management of T2DM, obesity and non-alcoholic steatohepatitis
In addition, PYY(3-36) promotes weight loss by suppressing appetite and delaying gastric emptying, thus improving insulin resistance
FASEB J 29:1395 Riaz MS, Shaheen T, Batool N, Saleem S, Haris A, Hayat F, Riaz R (2015) Modulation of immune system by taking probiotic bacteria: especially focus on lactic acid bacteria
It is believed that Semaglutide will bring more surprises to people as the trial proceeds
Individual circumstances: While guidelines are in place, a doctor is ultimately responsible for making decisions appropriate for each patient
US$ 20.47
US$ 28.80
US$ 23.24
US$ 25.86
